2015 ESMO Preceptorship on Prostate Cancer Barcelona

Oncology Meeting Resources

15 Oct - 16 Oct, Barcelona, Spain

ESMO Preceptorship on Prostate Cancer

The aims of this Preceptorship were to learn the fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer; understand essentials in the assessment and multidisciplinary treatment of prostate cancer, and learn about advances in treatment and novel targets in prostate cancer.

On this page, you may download the PDF of presentations given at the 2015 ESMO Preceptorship on Prostate Cancer Barcelona to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Useful links

Presenter Presentation title Session title
T.M. de Reijke, NL Screening, investigations and staging classification Session 1 Screening, diagnosis and staging
F. Algaba, ES Diagnosis , and impact of pathology and on prognosis Session 1 Screening, diagnosis and staging
E. Castro, ES Aetiology , and genetics with clinical implications Session 1 Screening, diagnosis and staging
A. Horwich, UK Welcome from ESMO, objectives and scientific introduction Session 1 Screening, diagnosis and staging
S. Bhatia, IN Prostate Case Study Session 2 Localised prostate cancer
A. Horwich, UK Active surveillance in Early Prostate Cancer Session 2 Localised prostate cancer
V. Fonteyne, BE Localized Prostate Cancer: Role of radiotherapy Session 2 Localised prostate cancer
T.M. de Reijke, NL Role of surgery Session 2 Localised prostate cancer
L.L. Cha, IE Prostate Cancer with Normal PSA: A Growing Threat? Session 2 Localised prostate cancer
V. Fonteyne, BE This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation: Argument For Session 3 Advanced prostate cancer
T.M. de Reijke, NL Presentation with lymphadenopathy Session 3 Advanced prostate cancer
T.M. de Reijke, NL This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation: Argument Against Session 3 Advanced prostate cancer
G. Daugaard, DK Value and role of PSA as a tumor marker of response/relapse Session 3 Advanced prostate cancer
T.M. de Reijke, NL Urinary obstruction Session 3 Advanced prostate cancer
C. Davidson, IE Choroidal and Lung Metastases in a young man with CRPC Session 3 Advanced prostate cancer